» Articles » PMID: 32954446

Differences in Liver Parenchyma Are Measurable with CT Radiomics at Initial Colon Resection in Patients That Develop Hepatic Metastases from Stage II/III Colon Cancer

Abstract

Background: Currently, there are no methods to identify patients with an increased risk of liver metastases to guide patient selection for liver-directed therapies. We tried to determine whether quantitative image features (radiomics) of the liver obtained from preoperative staging CT scans at the time of initial colon resection differ in patients that subsequently develop liver metastases, extrahepatic metastases, or demonstrate prolonged disease-free survival.

Methods: Patients who underwent resection of stage II/III colon cancer from 2004 to 2012 with available preoperative CT scans were included in this single-institution, retrospective case-control study. Patients were grouped by initial recurrence patterns: liver recurrence, extrahepatic recurrence, or no evidence of disease at 5 years. Radiomic features of the liver parenchyma extracted from CT images were compared across groups.

Results: The cohort consisted of 120 patients divided evenly between three recurrence groups, with an equal number of stage II and III patients in each group. After adjusting for multiple comparisons, 44 of 254 (17%) imaging features displayed different distributions across the three patient groups (p < 0.05), with the clearest distinction between those with liver recurrence and no evidence of disease. Increased heterogeneity in the liver parenchyma by radiomic analysis was protective of liver metastases.

Conclusions: CT radiomics is a promising tool to identify patients at high risk of developing liver metastases and is worthy of further investigation and validation.

Citing Articles

Assessing the Significance and Progression of Too Small to Characterize Lesions in Hepatic CT Scans of Patients With a Cancer History: A Two-Center Cross-Sectional Study.

Khoroushi F, Moeini M, Jarahi L, Hassannejad E, Kharghani F, Moodi Ghalibaf A Health Sci Rep. 2025; 8(3):e70374.

PMID: 40041777 PMC: 11872801. DOI: 10.1002/hsr2.70374.


Heterogenous liver parenchymal enhancement in CT is a favorable prognosis of HCC after hepatic resection.

Lin H, Peng Y, Chang C, Chang P, Peng P, Chang W Am J Cancer Res. 2024; 14(6):2984-2993.

PMID: 39005674 PMC: 11236790. DOI: 10.62347/MYNS2426.


Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessment.

Granata V, Fusco R, De Muzio F, Brunese M, Setola S, Ottaiano A Radiol Med. 2023; 128(11):1310-1332.

PMID: 37697033 DOI: 10.1007/s11547-023-01710-w.


CT radiomics analysis of primary colon cancer patients with or without liver metastases: a correlative study with [F]FDG PET uptake values.

Ahmed B, Sheikhzadeh P, Changizi V, Abbasi M, Soleymani Y, Sarhan W Abdom Radiol (NY). 2023; 48(11):3297-3309.

PMID: 37453942 DOI: 10.1007/s00261-023-03999-7.


Colorectal liver metastases patients prognostic assessment: prospects and limits of radiomics and radiogenomics.

Granata V, Fusco R, Setola S, Galdiero R, Maggialetti N, Patrone R Infect Agent Cancer. 2023; 18(1):18.

PMID: 36927442 PMC: 10018963. DOI: 10.1186/s13027-023-00495-x.


References
1.
Pugh S, Shinkins B, Fuller A, Mellor J, Mant D, Primrose J . Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial. Ann Surg. 2015; 263(6):1143-7. DOI: 10.1097/SLA.0000000000001351. View

2.
Shah M, Renfro L, Allegra C, Andre T, De Gramont A, Schmoll H . Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016; 34(8):843-53. PMC: 4872008. DOI: 10.1200/JCO.2015.63.0558. View

3.
Benson 3rd A, Schrag D, Somerfield M, Cohen A, Figueredo A, Flynn P . American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22(16):3408-19. DOI: 10.1200/JCO.2004.05.063. View

4.
Zheng J, Chakraborty J, Chapman W, Gerst S, Gonen M, Pak L . Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. J Am Coll Surg. 2017; 225(6):778-788.e1. PMC: 5705269. DOI: 10.1016/j.jamcollsurg.2017.09.003. View

5.
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A . Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244(2):254-9. PMC: 1602156. DOI: 10.1097/01.sla.0000217629.94941.cf. View